Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Fig. 5

Biosafety Assessment of Aβ11/T80@CSs. This figure presents the results of our biosafety evaluation. A We conducted in vitro hemolysis assays on various formulations, employing pure water as the positive control (PC) and saline as the negative control (NC). B The viability of bEnd.3 cells was examined following a 24-h incubation with different concentrations of free TGC, CSs-TGC (C), and Aβ11/T80@CSs-TGC (D). Additionally, histopathological examinations of the heart, liver, spleen, lungs, and kidneys were performed across the different groups, two days post-treatment (Panel E). All data are expressed as the mean ± SD, n = 3 independent experiments. Experiment E was repeated 3 times independently

Back to article page